CanSino issues urgent announcement after hitting daily limit up: mRNA cancer vaccine development still in early stage

证券时报··CNUS·Read original
3▲2 ▼0Impact / 5
Summary · why it matters

CanSino surged to the daily limit up on the last trading day before the National Day holiday, with its share price breaking through the previous consolidation range and reaching a new stage high since April 2023, while its H shares also moved higher in tandem. On October 1, CanSino issued a stock movement announcement stating that the company had noted recent market developments regarding mRNA technology, as well as the release or planned disclosure of overseas clinical stage data for mRNA cancer vaccines. CanSino made clear that the mRNA platform is one of the technology platforms in its portfolio, and that the company is developing preventive mRNA vaccines and therapeutic biologics, as well as related delivery systems. In the therapeutic area, it is advancing research and development of mRNA vaccines for indications including glioblastoma, rhabdomyosarcoma, and cervical cancer, as well as the development of In Vivo CAR-related therapies, all of which are currently in early stages. In August this year, Merck and Moderna jointly announced that their personalized messenger RNA cancer vaccine met its primary endpoint in a Phase III trial, making it the first therapeutic vaccine proven effective in a large-scale Phase III clinical trial globally. On August 25, CanSino's official WeChat account announced that its subsidiary CanSino Shanghai Biologics had formally signed a strategic cooperation framework agreement with Depush Hangzhou Biotechnology for the joint development of personalized therapeutic mRNA cancer vaccines. The two parties will jointly advance the research, development, and commercialization of personalized therapeutic mRNA cancer vaccines, with a global focus on gastrointestinal solid tumors and rare tumor treatment areas. It should be noted that CanSino's entire mRNA product line has not yet moved beyond the early research and development stage, and innovative drug development carries multiple uncertainties including technical failure, clinical results falling short of expectations, and approval delays, while competition in the domestic mRNA vaccine sector is also becoming increasingly intense.

Impact on assets 3

Biotech & Genomic Medicine▲
Merck & Company Inc
MRK
▲ PositiveTechnologyrelevance

Merck's partnered personalized mRNA cancer vaccine met its primary endpoint in a Phase III trial, the first such therapeutic vaccine success.

Moderna Inc
MRNA
▲ PositiveTechnologyrelevance

Moderna's jointly announced personalized mRNA cancer vaccine met its primary endpoint in a Phase III trial.

Others▲
Cansino Biologics Inc
688185
± MixedTechnologyrelevance

CanSino clarified its mRNA cancer vaccine programs (glioblastoma, rhabdomyosarcoma, cervical cancer, In Vivo CAR) remain in early stages despite the stock's limit-up.

Off-coverage companies 1

德普世（杭州）生物科技有限责任公司i
Private▲ PositiveDemandrelevance

Depush Hangzhou signed a strategic cooperation framework agreement with CanSino Shanghai Biologics to jointly develop personalized therapeutic mRNA cancer vaccines.